ArticleDrug delivery and translational research2026
Development, in silico, in vitro, and in vivo evaluation of gatiserts: HME-based ophthalmic inserts for prolonged ocular delivery of gatifloxacin.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanosuspension-based Ocular Therapeutics for Infection Control: Integrating Mucin Interactions and Tear Film Dynamics.AAPS PharmSciTech · 2026Review
- Emerging ophthalmic drug delivery.Drug delivery and translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to develop and characterize hot-melt extrusion (HME)-based gatifloxacin-loaded ophthalmic inserts (Gatiserts) to enhance ocular retention and reduce dosing frequency for bacterial conjunctivitis management. Gatiserts were formulated using hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), and Poloxamer 407 via HME, ensuring uniform drug-polymer distribution. CaliCut technology enabled precise cutting, achieving consistent insert dimensions. Physicochemical characterization included XRD, DSC, ATR-FTIR, and SEM/EDS. In vitro drug release and kinetic modeling were performed, while molecular dynamics simulations assessed polymer-mucin interactions (MUC-1, MUC-4, MUC-16) to predict mucoadhesion. In vitro, antimicrobial activity against Staphylococcus aureus and Escherichia coli was performed, and in vivo, ocular irritation studies were conducted in rabbits. The optimized formulation (F10) exhibited well-defined dimensions (1.27 mm diameter, 3.5 mm length) with uniform drug distribution, attributed to HME and CaliCut precision. In vitro studies demonstrated sustained drug release (82.07% over 9 h), following Peppas-Sahlin kinetics (R² = 0.9874). Molecular simulations indicated strong polymer-mucin interactions (docking scores: -9.7 to -10.3 kcal/mol), suggesting enhanced mucoadhesion. XRD and DSC confirmed amorphous drug dispersion, while ATR-FTIR and SEM/EDS validated chemical stability and homogeneous drug distribution, respectively. In vitro, antimicrobial studies showed potent inhibition of S. aureus and E. coli over 24 h. Gatiserts exhibited excellent biocompatibility (Draize score: 0) with no ocular irritation. The prolonged drug release, enhanced mucoadhesion, and excellent biocompatibility of Gatiserts suggest their potential for a significantly reduced dosing frequency compared to conventional eye drops, addressing rapid precorneal clearance and improving patient compliance in bacterial conjunctivitis management.
Indexed as
Identifiers
41225245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.